Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Merck KGaA
  6. News
  7. Summary
    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck KGaA's Multiple Sclerosis Treatment Drug Shows Improved Quality Of Life In Study

10/13/2021 | 07:55am EST


ę MT Newswires 2021
All news about MERCK KGAA
09:10aTech Stocks Rally Premarket Tuesday
MT
08:26aMerck KgaA Unit to Spend $1 Billion in US to Tackle Semiconductor Shortage
MT
07:45aPalantir Technologies Partners With Merck KGaA to Provide Athinia Analytics Platform fo..
MT
07:20aGerman chip chemical supplier to spend $1 billion in U.S., pairs with Palantir on suppl..
RE
12/06MARKETMIND : Chasing the Omicron dip
RE
12/03MARKETMIND : Omicron and payrolls (TGIF)
RE
12/02MARKETMIND : Vol takes a toll
RE
12/01MARKETMIND : Transitory, you are toast
RE
11/30EMD Serono Launches New Fertility LifeLines Portal to Increase Support and Access for P..
AQ
11/26MERCK - 54% of Europeans consider their current physical health to be good or very good..
AQ
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Financials
Sales 2021 19 604 M 22 060 M 22 060 M
Net income 2021 2 956 M 3 326 M 3 326 M
Net Debt 2021 9 058 M 10 193 M 10 193 M
P/E ratio 2021 31,7x
Yield 2021 0,73%
Capitalization 94 042 M 106 B 106 B
EV / Sales 2021 5,26x
EV / Sales 2022 4,81x
Nbr of Employees 59 308
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 216,30 €
Average target price 214,19 €
Spread / Average Target -0,98%
EPS Revisions
Managers and Directors
BelÚn Garijo Lˇpez Chairman-Executive Board & CEO
Marcus Kuhnert Chief Financial Officer
Wolfgang Heinz BŘchele Chairman-Supervisory Board
Maria Rivas Chief Medical Officer & Senior Vice President
Laura Matz Chief Science & Technology Officer
Sector and Competitors